GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » EPS (Diluted)

Mankind Pharma (BOM:543904) EPS (Diluted) : ₹35.95 (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma EPS (Diluted)?

Mankind Pharma's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was ₹11.31. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹35.95.

Mankind Pharma's EPS (Basic) for the three months ended in Dec. 2023 was ₹11.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹35.99.

Mankind Pharma's EPS without NRI for the three months ended in Dec. 2023 was ₹11.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was ₹35.95.

During the past 12 months, Mankind Pharma's average EPS without NRIGrowth Rate was 95.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Mankind Pharma EPS (Diluted) Historical Data

The historical data trend for Mankind Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma EPS (Diluted) Chart

Mankind Pharma Annual Data
Trend Mar20 Mar21 Mar22
EPS (Diluted)
25.72 31.59 35.78

Mankind Pharma Quarterly Data
Mar20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.48 7.09 12.15 12.49 11.31

Competitive Comparison of Mankind Pharma's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mankind Pharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's PE Ratio falls into.



Mankind Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Mankind Pharma's Diluted EPS for the fiscal year that ended in Mar. 2022 is calculated as

Diluted EPS (A: Mar. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(14334.75-0)/400.588
=35.78

Mankind Pharma's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(4537.6-0)/401.202
=11.31

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹35.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mankind Pharma  (BOM:543904) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mankind Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Mankind Pharma (BOM:543904) Business Description

Traded in Other Exchanges
Address
262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020
Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines